Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy: Clinical Studies

Sanjay Popat, Adam Januszewski, Mary O’Brien, Tanya Ahmad, Conrad Lewanski, Ulrike Dernedde, Petra Jankowska, Clive Mulatero, Riyaz Shah, Jonathan Hicks, Tom Geldart, Mathilda Cominos, Gill Gray, James Spicer, Karen Bell, Simon Roitt, Clive Morris, Yenting Ngai, Laura Hughes, Allan HackshawWilliam Wilson*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy: Clinical Studies'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology